GSK Exercises Option To Progress Development Of ChemoCentryx’s Traficet-EN For The Treatment Of Inflammatory Bowel Diseases
GlaxoSmithKline (GSK) and ChemoCentryx, Inc. announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN(TM) (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn’s disease…
This entry was posted on Tuesday, January 12th, 2010 at 1:00 am and is filed under Irritable Bowel Syndrome. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.